GlassScriptPhysician profile
Amber Phelps
NPI 1639760382
$2,317.09
in general payments reported to CMS, 2019-2025
26 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.82 · 2024: $706 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,296.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $314.37 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $287.39 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Lundbeck LLC | $250.46 | 2024-2025 | Rexulti, Vyepti |
| Pfizer INC. | $178.84 | 2024-2025 | |
| Amgen INC. | $152.56 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Bausch Health US, LLC | $146.86 | 2025 | Aplenzin, Wellbutrin |
| Exact Sciences Corporation | $138.60 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $122.25 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Corium, LLC | $118.81 | 2024-2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.64 | 2024-2025 | Jardiance |
| Abbvie INC. | $91.19 | 2024-2025 | |
| Axsome Therapeutics, INC. | $58.37 | 2025 | Auvelity |
| Corcept Therapeutics | $49.44 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $41.43 | 2024-2025 | Trintellix |
| Xeris Pharmaceuticals, INC. | $31.56 | 2025 | Gvoke Hypopen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $30.44 | 2025 | Nuzyra |
| Seqirus USA INC | $27.86 | 2025 | Fluad, Flucelvax |
| Otsuka America Pharmaceutical, INC. | $27.02 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $26.44 | 2025 | Capvaxive, Gardasil 9 |
| Alnylam Pharmaceuticals INC. | $20.82 | 2021 | |
| Dexcom, INC. | $18.34 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $17.65 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.45 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.97 | 2024 | Caplyta |
| Glaxosmithkline, LLC. | $16.68 | 2024 | Trelegy Ellipta |
| Resmed Corp | $14.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Phelps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.